Serum Paraoxonase-1-Related Variables and Lipoprotein Profile in Patients with Lung or Head and Neck Cancer: Effect of Radiotherapy

Rodríguez-Tomàs, Elisabet; Murcia, M.; Arenas, Meritxell; Arguís, M.; Gil, María José; Amigó, Núria; Correig, X.; Torres, L.; Sabater, S.; Baiges-Gayà, Gerard; Cabré, Noemí; Luciano-Mateo, Fedra; Hernández-Aguilera, Anna; Fort-Gallifa, Isabel; Camps, Jordi; Joven, Jorge

doi:10.3390/antiox8070213

Cited by 18 publications

(19 citation statements)

References 48 publications

(53 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, PON1 activity is elevated in the serum of patients with colorectal cancer and tissues of patients with colon cancer [41]. In addition, since serum PON1 concentration is significantly reduced following radiotherapy, it can be used as an indicator of radiotherapy efficacy [42,43]. PON1 has also been extensively studied in HCC [44][45][46][47][48].…”

Section: Discussionmentioning

confidence: 99%

Identification and clinical validation of EMT-associated prognostic features based on hepatocellular carcinoma

Wang

et al. 2021

Cancer Cell Int

View full text Add to dashboard Cite

Background The aim of this study was to construct a model based on the prognostic features associated with epithelial–mesenchymal transition (EMT) to explore the various mechanisms and therapeutic strategies available for the treatment of metastasis and invasion by hepatocellular carcinoma (HCC) cells. Methods EMT-associated genes were identified, and their molecular subtypes were determined by consistent clustering analysis. The differentially expressed genes (DEGs) among the molecular subtypes were ascertained using the limma package and they were subjected to functional enrichment analysis. The immune cell scores of the molecular subtypes were evaluated using ESTIMATE, MCPcounter, and GSCA packages of R. A multi-gene prognostic model was constructed using lasso regression, and the immunotherapeutic effects of the model were analyzed using the Imvigor210 cohort. In addition, immunohistochemical analysis was performed on a cohort of HCC tissue to validate gene expression. Results Based on the 59 EMT-associated genes identified, the 365—liver hepatocellular carcinoma (LIHC) samples were divided into two subtypes, C1 and C2. The C1 subtype mostly showed poor prognosis, had higher immune scores compared to the C2 subtype, and showed greater correlation with pathways of tumor progression. A four-gene signature construct was fabricated based on the 1130 DEGs among the subtypes. The construct was highly robust and showed stable predictive efficacy when validated using datasets from different platforms (HCCDB18 and GSE14520). Additionally, compared to currently existing models, our model demonstrated better performance. The results of the immunotherapy cohort showed that patients in the low-risk group have a better immune response, leading to a better patient’s prognosis. Immunohistochemical analysis revealed that the expression levels of the FTCD, PON1, and TMEM45A were significantly over-expressed in 41 normal samples compared to HCC samples, while that of the G6PD was significantly over-expressed in cancerous tissues. Conclusions The four-gene signature construct fabricated based on the EMT-associated genes provides valuable information to further study the pathogenesis and clinical management of HCC.

show abstract

Section: Discussionmentioning

confidence: 99%

Identification and clinical validation of EMT-associated prognostic features based on hepatocellular carcinoma

Wang

et al. 2021

Cancer Cell Int

View full text Add to dashboard Cite

show abstract

“…PON1, due to its antioxidative function, may be involved in response to radiation-induced damage and prevent radiation-induced cell apoptosis. The possible correlation of serum PON1 activity with the risk of cancer recurrence after RT is not yet fully explored, with few such studies described in the literature and none about PCa [ 11 , 14 , 15 ].…”

Section: Introductionmentioning

confidence: 99%

Serum Paraoxonase-1 Activity and the Risk of Prostate Cancer Recurrence in Patients Treated with Radiotherapy

Jasiński

Olszewska−Słonina

2022

Antioxidants

View full text Add to dashboard Cite

The antioxidant paraoxonase-1 (PON1) may be involved in the response to radiation-induced oxidative stress and possibly prevent cell apoptosis. The correlation of PON1 with the risk of cancer recurrence after radiotherapy (RT) is not yet explored. We investigated changes in the activity of PON1 in patients with prostate cancer (PCa) undergoing RT, and the relation of PON1 activity to the risk of recurrence after RT. We included 56 men with PCa. Blood samples were obtained before irradiation and after the completion of RT. Patients were followed for an average of 51.2 months. Each case of biochemical recurrence was confirmed with biopsy. The control group was composed of 60 healthy men. There was no significant difference in PON1 activity between the control group and patients pre-radiotherapy. Irradiation was associated with a significant decrease in PON1 activity. Patients with PCa recurrence had significantly higher serum PON1 activity than those recurrence-free, both before and after RT. PON1 activity was a predictor of PCa recurrence, with sensitivity over 80% and specificity over 64%. Our results suggest that PON1 activity may be a predictor of PCa recurrence risk after RT. Studies with a larger number of patients and longer follow-up are needed to confirm this hypothesis.

show abstract

“…A recent meta-analysis showed decreased serum PON1 activity in patients with cancer, suggesting an impaired ability to combat oxidative stress, with potential implications in cell proliferation, promotion of genetic instability, and alterations in cellular sensitivity to chemotherapy [ 12 ]. We have shown previously that RT was associated to an increase in serum PON1 levels in cancer patients [ 13 , 14 ].…”

Section: Introductionmentioning

confidence: 99%

Identification of potential metabolic biomarkers of rectal cancer and of the effect of neoadjuvant radiochemotherapy

et al. 2021

Self Cite

View full text Add to dashboard Cite

We report a pilot study on the feasibility of determinations of circulating levels of paraoxonase-1 (PON1) and compounds related to energy metabolism as biomarkers for the evaluation of patients with rectal cancer (RC), and the effects produced by neoadjuvant radiochemotherapy (NRCT). We studied 32 patients treated with radiotherapy plus capecitabine concomitant chemotherapy and 48 control subjects. We identified pre-NRCT PON1 and α-ketoglutarate as the parameters that best discriminated between RC patients and the control group. Receiver operating characteristics analysis of the combination of the two parameters showed an area under the curve (AUC) of 0.918. Moreover, patients who presented a pathological complete response (pCR) to treatment had lower plasma pre-NRCT valine concentrations (AUC of 0.826). Patients who had a relapse had lower concentrations of succinate (AUC of 0.833). The results of the present study illustrate the usefulness of investigating alterations in oxidative stress and metabolism in RC. Due to the small number of patients studied, our results must be considered preliminary, but they suggest that the determination of circulating levels of PON1 and α-ketoglutarate might be a valuable tool for the early diagnosis of RC, while the determination of valine and succinate might effectively predict pCR and the appearance of relapse.

show abstract

Serum Paraoxonase-1-Related Variables and Lipoprotein Profile in Patients with Lung or Head and Neck Cancer: Effect of Radiotherapy

Cited by 18 publications

References 48 publications

Identification and clinical validation of EMT-associated prognostic features based on hepatocellular carcinoma

Identification and clinical validation of EMT-associated prognostic features based on hepatocellular carcinoma

Serum Paraoxonase-1 Activity and the Risk of Prostate Cancer Recurrence in Patients Treated with Radiotherapy

Identification of potential metabolic biomarkers of rectal cancer and of the effect of neoadjuvant radiochemotherapy

Contact Info

Product

Resources

About